Yahoo Poland Wyszukiwanie w Internecie

Search results

1. pmc.ncbi.nlm.nih.gov › articles › PMC11425063Effect of Semaglutide in Individuals With Obesity or Overweight...

   pmc.ncbi.nlm.nih.gov › articles › PMC11425063

   Several clinical trials have evaluated the efficacy and safety of semaglutide for weight management in individuals with obesity or overweight. These trials have demonstrated that semaglutide treatment is associated with clinically meaningful weight loss outcomes. Semaglutide is typically administered as a once-weekly injection.

2. pubmed.ncbi.nlm.nih.gov › 36254579Semaglutide for the treatment of overweight and obesity: A review

   pubmed.ncbi.nlm.nih.gov › 36254579

   18 paź 2022 · The Semaglutide Treatment Effect in People with obesity (STEP) clinical trial programme is evaluating once-weekly subcutaneous semaglutide 2.4 mg (a glucagon-like peptide-1 analogue) in people with overweight or obesity.

3. www.ajconline.org › article › S0002-9149(24)00319-9Long-Term Efficacy and Safety of Once-Weekly Semaglutide for...

   www.ajconline.org › article › S0002-9149(24)00319-9

   1 lip 2024 · In conclusion, semaglutide is efficacious for sustained weight loss in patients with overweight/obesity and without diabetes. Semaglutide is a glucagon-like peptide-1 receptor agonist that was previously used for the treatment of hyperglycemia in patients with type 2 diabetes.

4. pmc.ncbi.nlm.nih.gov › articles › PMC9486455Weight Loss Outcomes Associated With Semaglutide Treatment for...

   pmc.ncbi.nlm.nih.gov › articles › PMC9486455

   Weight Loss With Different Semaglutide Doses. In our study, 77 patients (44.0%) received the highest current doses of subcutaneous semaglutide (1.7 and 2.4 mg), while 98 (56.0%) received lower doses (0.25, 0.5, and 1 mg). Detailed information of the maximum dose reached by our cohort of patients is presented in eTable 2 in the Supplement.

5. www.nature.com › articles › s41591/024/02996-7Long-term weight loss effects of semaglutide in obesity without...

   www.nature.com › articles › s41591/024/02996-7

   13 maj 2024 · With semaglutide, lower BMI was associated with less percentage weight loss, and women lost more weight on average than men (−11.1% versus −7.5% treatment difference from placebo); however, in...

6. onlinelibrary.wiley.com › doi › 10Clinical review of subcutaneous semaglutide for obesity

   onlinelibrary.wiley.com › doi › 10

   Based on four Phase 3 trials, subcutaneous semaglutide as 2.4 mg once weekly was compared in efficacy and safety among 5000 randomized participants who were overweight or had obesity. A change in body weight from baseline to end of study was the primary outcome in the STEP program.

7. dom-pubs.onlinelibrary.wiley.com › doi › fullEfficacy and safety of semaglutide 2.4 mg for weight loss in...

   dom-pubs.onlinelibrary.wiley.com › doi › full

   28 lis 2023 · Therefore, we conducted this updated comprehensive review and meta-analysis to systematically explore and summarize the effectiveness and safety of weekly subcutaneous semaglutide 2.4 mg in the management of weight loss in non-diabetic obese or overweight individuals.